MA47111A - Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer - Google Patents
Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancerInfo
- Publication number
- MA47111A MA47111A MA047111A MA47111A MA47111A MA 47111 A MA47111 A MA 47111A MA 047111 A MA047111 A MA 047111A MA 47111 A MA47111 A MA 47111A MA 47111 A MA47111 A MA 47111A
- Authority
- MA
- Morocco
- Prior art keywords
- sirpgamma
- cancer
- treatment
- targeting agents
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438227P | 2016-12-22 | 2016-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47111A true MA47111A (fr) | 2019-10-30 |
Family
ID=61022415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047111A MA47111A (fr) | 2016-12-22 | 2017-12-19 | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230139592A1 (fr) |
| EP (1) | EP3559037A1 (fr) |
| MA (1) | MA47111A (fr) |
| WO (1) | WO2018118887A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018149938A1 (fr) | 2017-02-17 | 2018-08-23 | Ose Immunotherapeutics | Nouvelles utilisations d'anticorps anti-sirpg |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| EP3843772A2 (fr) * | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Polypeptides leurres |
| EP3986441A1 (fr) * | 2019-06-24 | 2022-04-27 | Amgen Inc. | Inhibition de la sirp-gamma pour le traitement du cancer |
| KR20230017219A (ko) | 2020-05-08 | 2023-02-03 | 일렉트라 테라퓨틱스, 인크. | Sirp 알파, sirp 베타 1, 및 sirp 감마 항체 및 이의 용도 |
| WO2023086906A2 (fr) * | 2021-11-10 | 2023-05-19 | Electra Therapeutics, Inc. | Anticorps sirp gamma et leurs utilisations |
| CN114085869A (zh) * | 2021-11-19 | 2022-02-25 | 许川 | 一种特异性表达人源性sirpg的转基因小鼠的构建方法及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US510997A (en) | 1893-12-19 | Water-closet | ||
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4311688A (en) | 1979-10-29 | 1982-01-19 | Serono Laboratories Inc. | Composition and method for cancer detection in humans |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5103098A (en) | 1989-11-09 | 1992-04-07 | Board Of Regents, The University Of Texas System | High resolution gamma ray detectors for positron emission tomography (pet) and single photon emission computed tomography (spect) |
| US5210421A (en) | 1991-06-10 | 1993-05-11 | Picker International, Inc. | Simultaneous transmission and emission converging tomography |
| US5208581A (en) | 1991-11-22 | 1993-05-04 | General Electric Company | High speed communication apparatus for computerized axial tomography (cat) scanners with matching receiver |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| US5446799A (en) | 1993-11-01 | 1995-08-29 | Picker International, Inc. | CT Scanner with improved processing efficiency 180 degrees+ fan angle reconstruction system |
| US5406479A (en) | 1993-12-20 | 1995-04-11 | Imatron, Inc. | Method for rebinning and for correcting cone beam error in a fan beam computed tomographic scanner system |
| US5600145A (en) | 1995-01-19 | 1997-02-04 | Picker International, Inc. | Emission/transmission device for use with a dual head nuclear medicine gamma camera with the transmission source located behind the emission collimator |
| US5608221A (en) | 1995-06-09 | 1997-03-04 | Adac Laboratories | Multi-head nuclear medicine camera for dual SPECT and PET imaging with monuniform attenuation correction |
| SE9602594D0 (sv) | 1996-07-01 | 1996-07-01 | Stefan Nilsson | Förfarande och anordning vid datortomografi |
| US5841140A (en) | 1997-01-08 | 1998-11-24 | Smv America, Inc. | Gamma camera for pet and spect studies |
| US5946371A (en) | 1997-12-08 | 1999-08-31 | Analogic Corporation | Method and apparatus for volumetric computed tomography scanning with offset symmetric or asymmetric detector system |
| US6115446A (en) | 1999-04-09 | 2000-09-05 | Arch Development Corp. | Fast reconstruction of fan-beam CT and SPECT |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| WO2006110728A2 (fr) | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Agregats de tegument immunogenes |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ, エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| WO2010037134A2 (fr) * | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Carcinogenese de cellules souches multietapes |
| KR102810907B1 (ko) | 2010-07-16 | 2025-05-21 | 아디맵 엘엘씨 | 항체 라이브러리 |
| WO2012009704A2 (fr) | 2010-07-16 | 2012-01-19 | Avantgen, Inc. | Nouveaux peptides et leurs utilisations |
| EP2934577A1 (fr) | 2012-12-19 | 2015-10-28 | Adimab, LLC | Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
| AU2015329696A1 (en) * | 2014-10-10 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
| CN114425077A (zh) * | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| US10946042B2 (en) * | 2015-12-01 | 2021-03-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for selective phagocytosis of human cancer cells |
-
2017
- 2017-12-19 US US16/470,719 patent/US20230139592A1/en active Pending
- 2017-12-19 WO PCT/US2017/067257 patent/WO2018118887A1/fr not_active Ceased
- 2017-12-19 EP EP17833041.1A patent/EP3559037A1/fr not_active Withdrawn
- 2017-12-19 MA MA047111A patent/MA47111A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230139592A1 (en) | 2023-05-04 |
| EP3559037A1 (fr) | 2019-10-30 |
| WO2018118887A1 (fr) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3416631T3 (pl) | Środki terapeutyczne do leczenia chorób neurodegeneracyjnych | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| PL4272834T3 (pl) | Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| MA45192A (fr) | Traitement d'association | |
| EP3431102A4 (fr) | Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3432888A4 (fr) | Traitement du cancer avec tg02 | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| EP3383404A4 (fr) | Traitement du cancer à l'aide de 2-désoxy-2-fluoro-l-fucose en association avec un inhibiteur de point de contrôle | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| EP3503904A4 (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3556368A4 (fr) | Agent thérapeutique contre l'onychomycose | |
| EP3490548A4 (fr) | Administration de promédicaments activés par l'hypoxie en combinaison à des agents immunomodulateurs pour le traitement du cancer | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| EP3347010A4 (fr) | Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra |